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(SLEDAI)Abstract Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with varied
manifestations and characterized by remission and flares of disease activity.
Aim of the work: The present study was undertaken to analyze the frequency, pattern and deter-
minants of disease flare in patients with SLE.
Patients and methods: Fifty-three SLE patients were prospectively enrolled. Systemic lupus ery-
thematosus disease activity index (SLEDAI) and numbers of lupus flare and their determinants
were evaluated monthly during the study period (6 months).
Results: The 53 patients were 51 females and 2 males (F:M 25:1). The age of the patients ranged
from 12 to 47 years (25.62 ± 7.57 years) with a mean disease duration of 3.13 ± 2.12 years. 71.69%
patients suffered from at least one episode of flare in the six month period. It was observed that
60% of flares occurred in patients with an initial disease activity score of >10. A significant corre-
lation was present between the initial SLEDAI score and the number of flares (p< 0.05). Non-
compliance (39.21%) was observed to be the leading factor in triggering a flare followed by infec-
tion (27.45%), summer season (5.88%), herbal medication (3.92%), psychological stress (3.92%),
acute gastritis (3.77%), cosmetics (1.96%) and inadequate dosing (1.96%). In 11.76% of flares
we were unable to identify any triggering factor for flare.
Conclusion: Although the disease course of SLE is highly unpredictable with frequent remissions
and exacerbations, few of the factors which have been identified can be avoided to reduce the occur-
rence of disease flare and help in lowering the morbidity and mortality.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Sciences
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Systemic lupus erythematosus (SLE) is the prototypic autoim-
mune disease characterized by the production of autoantibod-
ies to components of the cell nucleus in association with
diverse clinical manifestations encompassing almost all organ
systems [1]. It is chiefly mediated by immune complexes that
lead to inflammatory injury [2]. The etiology of SLE is still
not fully understood but multiple factors have been implicated
including development of autoantibodies [3], oxidative stress
[4], apoptosis [5] cytokine over production [6,7] and genetic
factors [8,9]. The interplay of these factors has a role in the
abnormal immune responses and pathogenesis of SLE. A num-
ber of environmental agents, such as cigarette smoke, viral
infection and various chemicals induce oxidative stress and
enhance autoimmunity [10].
It is a complex disease with variable presentations, course,
and prognosis, characterized by remissions and flares [1].
Lupus flares are triggered by various environmental factors
in genetically susceptible individuals [8]. According to Lupus
foundation of America, a flare is a measurable increase in dis-
ease activity in one or more organ systems involving new or
worse clinical signs and symptoms and/or laboratory measure-
ments. Flare can be considered as a reappearance of clinical
features which were earlier quiescent. It must be considered
clinically significant by the assessor and usually there
would be at least consideration of a change or an increase in
treatment [11].
The SLE disease activity index (SLEDAI), developed at the
University of Toronto in 1992, is a global score reflecting all
aspects of disease activity [12]. It is a weighted scale for 24
parameters and the score can range from zero to 105. An
increase in SLEDAI score of more than three was a flare, SLE-
DAI score that was within three points of the previous score
was persistent disease and a score of zero was remission.
Although infection is an established triggering factor for
flare in SLE, differentiating between active infection and
relapse is important. Active infection and sepsis from any
source as infections commonly complicate the course of SLE
and are among the most important causes of morbidity and
mortality in SLE patients [13]. All patients with SLE relapse
had increased erythrocyte sedimentation rate (ESR) level,
but C-reactive protein (CRP) was not, while with infection
ESR and CRP were regularly increased in all cases. Measuring
CRP in SLE is helpful in differentiating between infection and
relapse [14].
Disease activity was associated with an increased frequency
of comorbidities [15], functional disability and disease damage
[16]. A preventive measure of flare will go long way in reducing
morbidity and mortality of patient suffering from SLE. But
there were no prospective studies on SLE flare from this part
of the country. The current study was taken up to study the
pattern of disease flare and their occurrence and also the deter-
minants of disease flare in patients with SLE.
2. Patients and methods
The present study was undertaken in the Department of Med-
icine, Assam Medical College, Dibrugarh, India during the
period from 1st May 2011 to 30th April 2012. It was a hospital
based prospective observational study. Patients satisfying the1982 American College of Rheumatology (ACR) criteria
(updated in 1997) for SLE were included in the study [17].
Fifty-three patients were included in this study and each was
followed up for a period of 6 months. Patients below 12 years
were excluded from the study. Approval of the hospital ethics
committee was taken. Informed consent was taken from every
patient.
All patients underwent baseline investigations for complete
hemogram and biochemical parameters, chest radiograph and
electrocardiogram (ECG). Immunological investigations
included antinuclear antibodies (ANA) by immunofluroscence
method, anti-dsDNA by enzyme linked immunosorbent assay
(ELISA) and complement levels (C3, C4) by Nephelometry.
Other special investigations were done as per clinical indica-
tion. The SLEDAI score was calculated on initial visit and
then monthly for six months.
There is no generally accepted definition of lupus flare at
present. In this study, flare was defined by encompassing (1)
SLEDAI score, (2) clinical disease activity scenarios that
may not be captured by the SLEDAI, and (3) change in
treatments.
Statistical analysis was done using statistical package for
social sciences (SPSS) software version 16. Data were pre-
sented as mean ± standard deviation and percentage. Correla-
tion was performed by Pearson correlation coefficient. p value
was considered significant if <0.05.3. Results
A total of 53 patients were included in the study. In the present
study the age of the patients ranged from 12 to 47 years. It was
observed that most of the patients (35.84%) were in the age
group of 21–25 years, followed by 26–30 years (28.30%).
Mean age in our patients was 25.62 ± 7.57 years. Of the 53
patients studied, only 2 (3.77%) were male and rest 51
(96.22%) were female with a male: female ratio of 1:25. Most
of the patients had disease duration of less than 1 year
(28.30%). Minimum duration was 7 days and maximum
duration was 11 years. Mean duration was 3.13 ± 2.12 years
(Table 1).
The most common clinical manifestation at enrollment was
mucocutaneous features (86.79%) followed by renal (69.81%)
and musculoskeletal (56.60%). Other manifestations include
anemia (71.69%), pleuropericardial effusion (26.41%), gas-
trointestinal (45.28%) and neuropsychiatric symptoms
(32.07%). Antinuclear antibody (ANA) was positive in 51
(96.22%) of 53 patients and anti-dsDNA was positive in 51
(96.22%) patients. It was observed that higher was the titer
of anti dsDNA, more was the disease activity. A low comple-
ment level was found in 38 (71.69%) patients.
Out of 53 patients included in the study 38 (71.69%) expe-
rienced flare in the 6 months follow up period. A total of 51
flares were recorded during the study period and 29
(54.71%) patients had one flare in the six months follow up.
Most of the flares (66.66%) occurred when the initial disease
activity score was P10. Almost one third of patients
(28.29%) did not experience any flare during the follow up per-
iod. Those patients came for regular follow up and were
strictly adherent to treatment. The most number of flares
(35.29%) were seen in the age group of 26–30 years followed
closely by 21–25 years (31.37%) (Table 2). It was observed that
Table 2 Number of flares in the systemic lupus erythematosus
patients.
Number of flares n (%)
0 15 (28.3)
1 29 (54.7)
2 5 (9.43)
3 4 (7.54)
Table 3 Flares in pregnancy and post partum period in the
systemic lupus erythematosus patients.
Features Number of patients Number of flares
Pregnancy 1 0
Post partum 2 5
Total 3 5
Table 4 Relation of estimated initial disease activity with the
number of flares in the systemic lupus erythematosus patients.
Initial
SLEDAI
Score
SLE
patients (n)
Flares
(n)
Patient:flare
ratio
% of total
flares
0–9 26 17 1:0.6 33.3%
10–19 17 21 1:1.23 41.2%
20–29 09 11 1.1.22 21.6%
P30 01 02 1:2 3.9%
Total 53 51 1:0.96
Table 5 Various determinants of flare encountered in the
study in the systemic lupus erythematosus patients.
Determinants n (%) Flares in SLE patients
(n= 53)
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age groups (16–30 years) (Table 3). It was observed that
60% of flares occurred in patients with an initial SLEDAI dis-
ease activity score of >10. There was a remarkable relation
seen between mean SLEDAI score and the number of flares
suffered which was found to be significant (p< 0.05)
(Table 4).
It was observed that in our study the commonest factor
leading to a flare was non compliance (39.21%), followed by
infection (27.45%) with a few patients having increased flare
during summer season (5.66%) and a few having a history of
use of herbal medication (3.92%). A small number of patients
had a combination of various factors. In the present study it
was observed that two of the flares were preceded by psycho-
logical stress. It has been found that 2 patients progress to flare
after having symptoms of acute gastritis. In a good number of
patients (11.76%) no preceding events were found (Table 5).
This shows that many factors triggering a flare are still
unknown and that may lead to a very unpredictable course
of illness.
After taking herbal medications two patients had to be hos-
pitalized with high disease activity and vastly deranged hepatic
and renal parameters. After completion of their 6 months
follow-up, 5 patients died later during the study period.
4. Discussion
SLE is a global disease and the prevalence of SLE varies
worldwide in different racial groups and geographical areas,
with an average annual incidence of 1.8–7.6/100,000 popula-
tions/year [18]. Flare is a term used to imply a clinically signif-
icant increase in disease activity compared with baseline. The
exact cause or triggering factor resulting in flare in SLE is
not known though various environmental and genetic factors
have been implicated, so it is difficult to predict or prevent
such events.
Out of 53 patients included in the study 38 (71.69%)
patients had experienced flare in the 6 months follow up per-
iod. A total of 51 flares were recorded during the study period.
29 (54.71%) patients had one flare in the six months follow up.Table 1 Age distribution and duration of illness in the
systemic lupus erythematosus patients.
SLE patients (n= 53) n (%)
Age group (years)
615 3 (5.66)
16–20 8 (15.09)
21–25 19 (35.84)
26–30 15 (28.3)
31–35 2 (3.77)
36–40 3 (5.66)
>40 3 (5.66)
Disease duration (years)
<1 15 (28.3)
1–2 10 (18.86)
2–3 6 (11.32)
3–4 9 (16.98)
4–5 4 (7.54)
>5 9 (16.98)
SLE: systemic lupus erythematosus.
Non Compliance 20 (39.2)
Infection
Tuberculosis 2 (3.9)
Others 12 (23.5)
Summer Season 3 (5.9)
Herbal Medication 2 (3.9)
Psychological stress 2 (3.9)
Acute Gastritis 2 (3.9)
Application of new cosmetics 1 (1.96)
Inadequate dosing 1 (1.96)
No cause 6 (11.8)
Total 51 100%The most no. of flares (35.29%) was seen in the age group of 26
to 30 years followed closely by 21 to 25 years (31.37%). It was
observed that 60% flare occurred in the 3rd decade an 80% of
flares occurred in the age group of 16–30 years.
It was observed that in our study the commonest
factor leading to a flare was non compliance (39.21%). Such
a high incidence of non compliance may be because of low
S58 S. Kakati et al.socioeconomic status leading to inability to buy adequate
medicines and difficulty to come for regular follow up. A sim-
ilar observation has been reported by other studies across the
globe [19,20].
Non compliance was closely followed by infections
(27.45%). The infection rate is high in SLE patients as pro-
jected by different study groups globally [21,22]. Different risk
factors postulated for increase in infections are use of immuno-
suppressive drugs and steroid therapy. Early diagnoses of
infections are very important as they commonly complicate
the course of SLE and can cause increased morbidity and mor-
tality. However, it is not always easy to differentiate infection
and relapse in patients with SLE. Measuring ESR and CRP
may help to differentiate between infection and relapse, as
patients with infection will have both high ESR and CRP
but with relapse only ESR will be high not CRP [14].
Another finding in our study is the use of herbal medication
(3.92%). Herbal medication taken by the patients were of
unknown composition and after taking them the patient had
to be hospitalized with high disease activity and vastly
deranged hepatic and renal parameters. Further study about
herbal medication practiced in these parts is required. Some
herbs which should be avoided by lupus patients are Echi-
nacea, garlic and alfalfa sprouts all of which can lead to flares
[23]. Chinese herbal medicine appears to be suitable as an
adjunct to modern medical therapies. While earlier Chinese
reports suggested that these herbs alone could function reason-
ably well as a treatment for lupus [24,25], this approach
appears to have been largely abandoned in Chinese hospitals.
SLE disease exacerbation with seasonal variation is often
described in the literature. In the present study, 3 patients
(5.66%) were recorded with increased disease activity in the
summer season. There is a post-summer increase in the fre-
quency and severity of visceral lupus spreading correlated to
cutaneous exacerbation and sunlight [26]. It has been advo-
cated that keeping a warm living environment and avoiding
exposure to extremes of temperature may help to reduce flare
for SLE patients in subtropical countries [27].
In our study it was observed that two of the flares were pre-
ceded by psychological stress. Similar findings were also
observed in other studies especially daily stress with social rela-
tionships and social duties may be factors to be related to the
course of disease activity in SLE [28]. There has been a report
of stress as an exacerbating factor in the activity and to have
an impact on quality of life but not as a provoking factor
for SLE [29].
One of the important findings observed in the present study
is progress to flare after having symptoms of acute gastritis in
two patients. But it could not be established in the study
whether the acute gastritis leads to the patients having a flare
or whether those symptoms were gastrointestinal manifesta-
tions of the disease itself. No studies have been found regard-
ing this association. There is a need for further research to look
for this association.
Surprisingly, preceding events could not be found in
11.76% flares. It can be concluded that many of the factors
leading to increased flare are still not known and that may con-
tribute to the unpredictable course of illness in many patients.
SLE flare during pregnancy has a worse prognosis and it is
very difficult to differentiate SLE flare and preeclampsia and
occasionally both coexist. During pregnancy, SLE flares are
associated with aPL antibodies, increased disease activity atonset of pregnancy, thrombocytopenia, lupus nephritis,
arterial hypertension and they are often associated with fetal
complications [30]. In the present study, 2 patients were in
the early post partum period and together recorded 5 flares.
They had presented with flare as both the patients had stopped
taking medications during pregnancy and post partum period
without consultation with any health practitioner and were
lost to follow up. Even after starting high dose steroids and
immunosuppressive pulse therapy, complete remission was dif-
ficult to achieve with the patients reporting frequent flares in
pregnancy [31]. Only one pregnant patient was followed up
during the study period and no flare was recorded in the six
months.
The disease activity was calculated using the SLEDAI scor-
ing system. It was observed that 60% of flares occurred in
patients with an initial disease activity score of >10. There
was a significant correlation between mean SLEDAI score
and the number of flares suffered (p< 0.05). But it is the high
persistent disease activity (weighted average of SLEDAI scores
>10) rather than a high initial SLEDAI, a high maximum
SLEDAI, and an increase number of flares which is indepen-
dently associated with decreased survival [32].
The study is a small one and the follow up period is also for
only six months which is not adequate to establish the findings.
Flare was not studied according to the organ or system
involvement and there are overlapping of many factors in a
same patient leading to flare. Further study regarding factors
which may have a role in causing a flare is required.
Systemic lupus erythematosus presents itself in various clin-
ical manifestations and is subjected to frequent remissions and
exacerbations which are difficult to predict.
In conclusion, the present study showed that the disease
occurred most commonly in the young adult female patients.
Mucocutaneous manifestation was the commonest presenting
symptom. Most of the patients suffered at least one flare dur-
ing the period of study. A significant correlation was observed
between the SLEDAI score and the number of flares. The com-
monest determinants among the patient having a flare were
noncompliance and infection. In a few patients no determinant
for flare could be ascertained. So, even if the disease course of
SLE is highly unpredictable with frequent remissions and exac-
erbations, few of the factors which have been identified can be
avoided to reduce the occurrence of disease flare and help in
lowering the morbidity and mortality.Conflict of interest
None.
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